Haider David Andazola helps healthcare and biotech companies navigate statutory and regulatory issues involving the Center for Medicare & Medicaid Services (CMS), the Health Resources and Services Agency (HRSA) and the Food and Drug Administration (FDA). He regularly helps medical product clients resolve coverage and reimbursement issues under the Medicare and Medicaid programs, including the 340B program. As part of this work, Haider advises clients on requirements governing agency authority under the Administrative Procedure Act (APA) and has successfully advocated for policy changes through interim final rulemaking. He also has extensive experience advising gene therapy companies on policies relating to value-based purchasing arrangements and health care reform generally.
More »
Ten Things to Watch for in the Forthcoming Block Grant Guidance (UPDATED)
9 months ago